MwanzoNOVN • SWX
add
Novartis AG
Bei iliyotangulia
CHF 91.56
Bei za siku
CHF 92.04 - CHF 93.99
Bei za mwaka
CHF 83.63 - CHF 102.72
Thamani ya kampuni katika soko
205.76B CHF
Wastani wa hisa zilizouzwa
2.97M
Uwiano wa bei na mapato
12.39
Mgao wa faida
3.52%
Ubadilishanaji wa msingi
SWX
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 13.17B | 8.93% |
Matumizi ya uendeshaji wa biashara | 5.52B | -24.45% |
Mapato halisi | 3.19B | 81.09% |
Kiwango cha faida halisi | 24.21 | 66.28% |
Mapato kwa kila hisa | 2.06 | 18.39% |
EBITDA | 5.50B | 88.62% |
Asilimia ya kodi ya mapato | 5.91% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 13.85B | 8.08% |
Jumla ya mali | 103.52B | -8.14% |
Jumla ya dhima | 60.08B | -19.30% |
Jumla ya hisa | 43.44B | — |
hisa zilizosalia | 2.00B | — |
Uwiano wa bei na thamani | 4.23 | — |
Faida inayotokana na mali | 10.97% | — |
Faida inayotokana mtaji | 15.05% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | 3.19B | 81.09% |
Pesa kutokana na shughuli | 6.29B | 16.88% |
Pesa kutokana na uwekezaji | -374.00M | 83.09% |
Pesa kutokana na ufadhili | -382.00M | 54.09% |
Mabadiliko halisi ya pesa taslimu | 5.71B | 275.39% |
Mtiririko huru wa pesa | 4.55B | -63.57% |
Kuhusu
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
29 Feb 1996
Makao Makuu
Tovuti
Wafanyakazi
76,057